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Abstract
Background: Increased vascularity is a crucial event in the tumor progression and has prognostic significance in
various cancers. However, the ultimate role of angiogenesis in the pathogenesis and clinical outcome of vulvar
carcinoma patients is still not settled.
Methods: Tumor vascularity using CD34 stained slides measured by Chalkley counting method as well as hypoxia-
inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) immunoexpression was examined in 158
vulvar squamous cell carcinomas. Associations between vascular Chalkley count, HIF-1α and VEGF expression and
clinicopathological factors and clinical outcome were evaluated.
Results: High CD34 Chalkley count was found to correlate with larger tumor diameter (P = 0.002), deep invasion
(P < 0.001) and HIF-1α (P = 0.04), whereas high VEGF expression correlate significantly with poor tumor
differentiation (P = 0.007). No significant association between CD34 Chalkley counts and VEGF expression and
disease-specific survival was observed. High HIF-1α expression showed better disease specific survival in both
univariate and multivariate analyses (P = 0.001).
Conclusions: A significant association between high tumor vascularity and larger tumor size as well as deeper
tumor invasion suggests an important role of angiogenesis in the growth and progression of vulvar carcinomas.
HIF-1α expression in vulvar carcinomas was a statistically independent prognostic factor.
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Background
Vulvar carcinoma is accounting for 3-5% of all gyneco-
logical cancer and with an incidence ranging from 1 to 2
per 100 000 person-years worldwide [1,2]. The median
age of these patients has been about 70 years. However,
recently vulvar carcinomas are seen more frequently in
younger patients [3,4]. The prognostic evaluation and
treatment of vulvar carcinoma patients have been primar-
ily guided by the lymph node status, the size of the tumor,
depth of invasion, stage of the disease and grades [5-7].
Radical surgery is the most common treatment, but is
often accompanied with physical and psychological ad-
verse effects [5,8]. In an attempt to reduce severe compli-
cations, a change to individualized therapy has been
reported [9]. Thus, identification of new markers which
indicate the tumor behavior would be important to guide
treatment decisions.
Angiogenesis is a crucial event for tumor growth and
progression beyond a tumor size of 1–2 mm. Therefore,
tumor neovasculature makes an important target for
antiangiogenic therapy [10,11]. Increased tumor vascu-
larity has been shown to have prognostic significance in
various cancers including vulvar cancer [12-15]. The role
of increased tumor vascularity in disease progression of
various malignant gynecologic lesions, including malignant
vulvar lesions, has been described [16,17]. Its importance in
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vulvar cancer has been emphasized by the increased
vascularity in preinvasive lesions and invasive vulvar
carcinomas [15-21]. Vulvar carcinoma patients with in-
creased vascularity were reported to have poor progno-
sis in some studies [6,15,19], whereas other showed no
significance [20].
Hypoxia-inducible factor (HIF)-1α, a transcription fac-
tor, is a key regulator of angiogenesis when a growing
tumor experiences hypoxic stress and acts through vari-
ous intracellular signalling pathways. Such activation re-
sults in the secretion of vascular endothelial growth
factor (VEGF) and other factors related to tumor metab-
olism necessary for hypoxia compensation and tumor
cell survival [22]. It is known to be expressed in various
solid tumors including vulvar squamous cell carcinomas
[23-30]. The relation between primary tumor vascularity
and HIF-1α expression in head and neck and oeso-
phageal squamous cell carcinoma has been reported
[24,25], and the prognostic impact of HIF-1α expression
in cancer is varied [26,27,29-32]. HIF-1α expression in-
vestigated recently in normal epithelium, intraepithelial
neoplasia and invasive carcinoma of vulva did not show
significant differences [28]. To our knowledge, no study
of HIF-1α expression and its connection with prognosis
in vulvar carcinoma patients has been reported. VEGF, a
potent angiogenic molecule over-expressed in a hypoxic
state, is crucial to induce tumor angiogenesis and acts
through the receptors VEGFR1 and VEGFR2 [22,33]. It
is expressed in various human cancers including vulvar
malignancy [21,28,34,35]. A significant variation in ex-
pression of VEGF in nonneoplastic epithelium, preneo-
plastic lesions and invasive squamous cell carcinoma of
vulva has been described [21,28,35]. Its expression in
vulvar cancer and relationship with vascularity has been
reported [19]. The prognostic impact of VEGF expres-
sion in invasive vulvar carcinoma is still not settled
[19,36].
In the present study, we have evaluated a large series
of primary vulvar squamous cell carcinomas for primary
tumor vascularity and expression of HIF-1α and VEGF
and elucidated their relationships with various clinico-
pathological parameters and clinical outcome.
Methods
Patient materials
A retrospective study was performed on a cohort of 158
patients with vulvar squamous cell carcinoma. All pa-
tients had undergone a resection at The Norwegian Ra-
dium Hospital between 1977 and 2006. The median age
at diagnosis was 75 years (range, 41–92 years). In 108
(68%) of these cases radical surgery (a total vulvectomy
plus a bilateral inguinal lymphadenectomy) had been
performed, whereas the remaining 50 (32%) patients had
non-radical surgery. Postoperative therapy had been
administered to 44 patients including irradiation in 40
(25%) cases and irradiation/chemotherapy in four (3%)
cases. Seventy-four (47%) of the patients died as a result
of their vulvar cancer. All patients were followed up
from the time of their confirmed diagnosis until death
or 1. September, 2009. The median follow-up time for pa-
tients still alive was 108 months (range, 43 to 347 months).
All tumors were staged based on the new International
Federation of Gynecology and the Obstetrics (FIGO) clas-
sification from 2009 [37]. The Regional Committee for
Medical Research Ethics South of Norway (S-06012), The
Social and Health Directorate (04/2639 and 06/1478) and
The Data Inspectorate (04/01043) approved the current
study protocol. In this study we have used paraffin embed-
ded tumor tissue from vulvar cancer patients diagnosed
between 1977 and 2006. As many of these patients are
dead or very old we did not have the opportunity to obtain
patient consent. Permission to perform this study without
patient consent was obtained from The Social and Health
Directorate (04/2639).
Histological specimens were reviewed by the co-
author J.M.N. without access to any clinical information
on the patients. The tumors were classified according to
the World Health Organization recommendations [38].
All 158 tumors were classified as keratinizing/non-kera-
tinizing squamous cell carcinomas.
Immunohistochemistry
Three micrometer sections were processed for immuno-
histochemistry using the Dako EnVision™ Flex+ System
(K8012; Dako, Glostrup, Denmark) and the Dako Auto-
stainer. Deparaffinization and the unmasking of epitopes
were performed using PT-Link (Dako) and EnVision™ Flex
target retrieval solution at a high pH. After treatment with
0.03% hydrogen peroxide (H2O2) for 5 min to block
endogenous peroxidase activity, the sections were incu-
bated with monoclonal antibodies raised against CD34
(30 min at room temperature, clone QBEND-10, 1:1000,
1μg IgG1/ml) purchased from Monosan (Uden, The
Netherlands), HIF-1α (over night at 4°C, clone 54/HIF-1α,
1:100, 2.5 μg IgG1/ml) purchased from BD Transduction
Laboratories™ (San Jose, CA, USA) and VEGF (over night
at 4°C, clone VG1, 1:100, 0.45 μg IgG1/ml) purchased
from Dako. Then the slides were incubated with EnVi-
sion™ Flex+ mouse linker (15 min), EnVision™ Flex/HRP
enzyme (30 min) and 3’3-diaminobenzidine tetrahy-
drochloride (DAB) (10 min). After counterstaining with
hematoxylin the samples were dehydrated and mounted
in Richard-Allan Scientific Cyto seal XYL (Thermo
Scientific, Waltham, MA, USA). All of the sample series
included positive controls known to be positive for CD34,
HIF-1α and VEGF. As negative controls, the primary anti-
bodies were replaced with mouse myeloma protein IgG1
at the equivalent concentration.
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Quantification of tumor vascularity
Chalkley method was used for quantification of tumor
vascularity as recommended in a consensus meeting
[39]. The method has been described in detail earlier
[14]. Three most vascularized areas in the CD34 stained
tumor section known as “hotspots” were identified
under the low power magnification after scanning
first at ×40 and then ×100 magnification following the
Weidner’s method of selection of vascular hotspots [40].
Then a 25 point Chalkley eyepiece graticule fixed in one
of the eyepieces of the microscope was applied to each
vascular hotspot at ×200 magnification [Chalkley grid
area of 0.1886 mm2 (Nikon microscope, Eclipse E400)]
in such a way that maximum number of black dots in
Chalkley graticule fell on or within immunostained
microvessels. The number of these dots that have fallen
on or within the immunostained microvessels were
counted in each selected hotspot area and recorded as
Chalkley count. Sclerotic and necrotic area was avoided
and count was done in only invasive carcinoma including
margin. The highest count among the 3 hotspots counts
from each tumor was used for further analyses. Measure-
ment of vascularity was performed without the knowledge
of clinicopathological data or clinical outcome.
Evaluation for HIF-1α and VEGF expression
Expression of HIF-1α was evaluated on immunostained
slides semiquantitatively into four classes and only nuclear
immunoreactivity of the tumor cells was taken into ac-
count. Due to similar staining intensity of the HIF-1α
positive cases we did not consider the intensity of immu-
nostaining. Based on the number of HIF-1α positively
stained tumor cells, tumors were grouped into: 0% of the
cells; < 10% of the cells; 10-50% of the cells and > 50% of
the cells. For further analyses, HIF-1α expression in nu-
cleus in more than 50% of the tumor cells was considered
as high. VEGF positive cases showed different staining in-
tensity and both intensity and number of positive tumor
cells were evaluated. Cytoplasmic expression of VEGF was
categorized semiquantitatively on the basis of intensity of
the signal (absent, 0; weak, 1; moderate, 2; strong, 3) and
the percentage of positive tumor cells (absent, 0; < 10%, 1;
10-50%, 2; > 50%, 3). The composite score was calculated
as fraction of positive tumor cells score multiplied by in-
tensity score, and range from 0 to 9. For further analyses,
cytoplasmic VEGF immunostaining with a composite
score ≥ 6 was classified as high expression. Examination of
immunostaining was performed in a blinded fashion with
no knowledge of the clinicopathological variables and pa-
tient outcomes.
Statistical analyses
The associations between the HIF-1α and VEGF expression
and CD34 Chalkley counts of primary tumor vascularity
and the clinicopathological variables were evaluated by
the Pearson chi-square (χ2), Fisher’s exact test and linear-
by-linear association as required. The disease-specific sur-
vival analysis, based on death from vulvar cancer only, was
performed using the Kaplan Meier method and P value
computed by log-rank test. A Cox proportional hazards
regression model was used for both univariate and multi-
variate evaluation of survival rates. In the multivariate
analysis, a backward regression was performed and vari-
ables with a P ≤ 0.05 in univariate survival analysis were
included in the model. The vulvar carcinoma tissues in
our cohort have been collected over an extensive period
from 1977–2006. Due to the large variation in storage
time and given that the fixation protocol for these tissues
up to 1987 was acid formalin, whereas from 1987–2006
was buffered formalin, Mann–Whitney U test was per-
formed to evaluate whether this has any influence on the
CD34, HIF-1α and VEGF immunostaining. The Mann–
Whitney U test showed that the distribution of CD34,
Figure 1 Representative images of CD34 staining of primary
vulvar carcinoma vascularization. (A) Low vascularity (low Chalkley
count) and (B) High vascularity (high Chalkley count). Images were
taken by a Leica DFC 320 digital camera with a Plan-neofluar 10×
objective lens in Axiophot microscope (Zeiss Germany).
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HIF-1α and VEGF expression was the same between sam-
ples processed before and after 1987. All analyses were
processed using the SPSS 18.0 statistical software package
(SPSS, Chicago, IL). Statistical significance was considered
for P < 0.05.
Results
Vascularization in vulvar squamous cell carcinoma was
heterogenously distributed. Microvessels were located in
the tumor stroma lying between the islands of tumor
cells and the size and shape of the vessels greatly varied.
The CD34 Chalkley counts for the vulvar carcinoma vas-
cularity ranged from 3–14 (mean, 7.92; median, 8; SD,
2.29). Predefined cutoff value of 8 (median value) was
used to dichotomize the tumor into high and low vascular
groups. Low (Chalkley counts < 8) and high (Chalkley
counts ≥ 8) vascularity was identified in 67 (42%) and 91
(58%) of the vulvar carcinomas, respectively (Figure 1A
and B). In vulvar carcinomas, high HIF-1α immunostain-
ing (> 50% tumor cells) in the nucleus was observed in 57
(36%) and low levels (≤ 50% tumor cells) in 101 (64%)
cases (Figure 2A and B), whereas high VEGF expression
(score ≥ 6) in the cytoplasm was identified in 63 (40%)
and low low level (score < 6) in 95 (60%) cases (Figure 2C
and D).
CD34 Chalkley count, HIF-1α and VEGF expression in
relation to clinicopathological parameters are shown in
Table 1. High CD34 Chalkley count was found to correl-
ate significantly with larger tumor diameter (P = 0.002)
and deeper invasion (P < 0.001), whereas high VEGF
expression correlate significantly with poor tumor diffe-
rentiation (P = 0.007). High level of HIF-1α was signifi-
cantly correlated to high CD34 Chalkley counts (P = 0.04).
VEGF expression did not show any association with
CD34 Chalkley count and HIF-1α levels.
In univariate survival analysis, high HIF-1α expression was
associated with better disease-specific survival (P = 0.001)
(Figure 3), whereas no significant association between
CD34 Chalkley counts and VEGF expression and disease-
specific survival (P = 0.16 and P = 0.45, respectively) was
observed. In multivariate analysis, lymph node metastases,
age and HIF-1α expression retained independent prognos-
tic significance (Table 2).
Discussion
We observed that primary tumor vascularity, quantified
by Chalkley method, had a significant association with
tumor size and depth of invasion in invasive vulvar car-
cinomas. Tumor size has been reported to predict local
lymph node metastasis [41] and is an important prog-
nostic marker in vulvar cancer patients. Tumor size is at
present used to stratify patients into different risk groups
and acts as a determinant for surgical treatment [6,7].
In vulvar carcinomas, depth of tumor invasion is also in-
dicative of the aggressiveness of primary tumor and is
reported to be associated with lymph node metastases
[41] and reduced survival [6]. Inguinofemoral lymph
node status is the most powerful indicator of poor prog-
nosis in vulvar cancer [42-44] and a significantly reduced
survival in the current study has been confirmed. In the
present study, no prognostic significance of tumor vas-
cularity was observed for patients with vulvar carcinoma.
Figure 2 Representative images of HIF-1α and VEGF immunoexpression in primary vulvar carcinoma. (A) high HIF-α nuclear expression
and (B) low HIF-α nuclear expression (C) high VEGF cytoplasmic staining and (D) low VEGF cytoplasmic staining. 40× objective lens.
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Table 1 CD34 Chalkley count, HIF-1α and VEGF expression in relation to clinicopathological variables in vulvar
carcinomas
Variable Total CD34 Chalkley count HIF-1α VEGF
N Low High (%) P value Low High (%) P value Low High (%) P value
Age 0.251 0.281 0.681
25–69 59 30 29 (49) 34 25 (42) 36 23 (39)
70–84 81 29 52 (64) 55 26 (32) 46 35 (43)
85+ 18 8 10 (56) 12 6 (33) 13 5 (28)
FIGO 0.672 0.222 0.082
Ia 0 0 0 (0) 0 0 (0) 0 0 (0)
Ib 77 35 42 (55) 51 26 (34) 48 29 (38)
II 7 2 5 (71) 4 3 (43) 7 0 (0)
IIIa 30 14 16 (53) 13 17 (57) 20 10 (33)
IIIb 26 8 18 (69) 18 8 (31) 11 15 (58)
IIIc 7 2 5 (71) 5 2 (29) 4 3 (43)
IVa 1 1 0 (0) 1 0 (0) 0 1 (100)
IVb 7 3 4 (57) 6 1 (14) 4 3 (43)
Not available 3
Lymph node metastasis 0.213 0.543 0.113
None 87 39 48 (55) 58 29 (33) 55 31 (37)
Unilateral 44 19 25 (57) 25 19 (43) 29 15 (34)
Bilateral 24 6 18 (75) 15 9 (38) 10 14 (58)
Not available 3
Tumor diameter (cm) 0.0021 0.951 0.981
0.3–2.5 32 19 13 (41) 19 13 (41) 20 12 (38)
2.6–4.0 51 24 27 (53) 33 16 (31) 30 21 (41)
4.1–20.0 72 21 51 (71) 44 28 (39) 44 28 (39)
Not available 3
Tumor differentiation 0.073 0.233 0.0073
Well 35 19 16 (46) 26 9 (26) 19 16 (46)
Moderate 92 32 60 (65) 54 38 (41) 64 28 (30)
Poor 31 16 15 (48) 21 10 (32) 12 19 (61)
Depth of invasion (mm) <0.0011 0.581 0.781
0.0–4.0 26 19 7 (27) 17 9 (35) 15 11 (42)
4.1–8.0 56 26 30 (54) 37 19 (34) 37 19 (34)
8.1–40.0 74 20 54 (73) 45 29 (39) 43 31 (42)
Not available 2
Infiltration of vessel 0.553 0.063 0.733
No 116 51 65 (56) 70 46 (40) 72 44 (38)
Yes 39 15 24 (62) 30 9 (23) 23 16 (41)
Not available 3
1Linear-by-linear association.
2Fisher’s exact test.
3Pearson chi-square.
Low: CD34 Chalkley count < 8; High: CD34 Chalkley count ≥ 8.
Low: HIF-1α in ≤ 50% tumor cells; High: HIF-1α in > 50% tumor cells.
Low: VEGF score < 6, High: VEGF score ≥ 6.
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This is in accordance with an earlier study on vulvar
cancer [20], but in contrast to others [6,15,19]. These
conflicting reports on primary tumor vascularity and
prognosis might be due to methodological differences,
different study cohort or biological factors [6,19,20]. We
used the Chalkley counting method for vascular quanti-
fication which measures the relative vascular area [45],
as recommended in a consensus meeting for quantifica-
tion of vascularity in solid tumors [39], whereas in other
studies microvessels have been counted manually [15,19,20]
or using image analyses [6]. Moreover, other studies
[6,15,19,20] had analysed smaller number of cases com-
pared to our large series of vulvar carcinomas. Thus,
our results of high tumor vascularity associated with
larger tumor size and deeper invasion (known patho-
logical markers for tumor aggressiveness) indicates
angiogenesis as a marker for the aggressive behaviour
of vulvar carcinoma.
HIF-1α, is a crucial molecule in inducing angiogenesis
in growing tumor under hypoxic stress [22] and several
reports have been published on relation between HIF-1α
expression and angiogenesis in head and neck and
oesophageal squamous cell carcinoma [24,25]. In present
study, we did observe a positive association between
HIF-1α expression and CD34 Chalkey count of primary
tumor vascularity similar to a report for head and neck
squamous cell carcinoma patients [25]. This confirms
the role of HIF-1α for the initiation and the promotion
of angiogenesis in vulvar cancer. High tumoral HIF-1α
expression is reported to be associated with reduced sur-
vival in oral, oropharyngeal and cervical cancers [29,32,46].
In contrast, in the present study, a significantly improved
survival of vulvar carcinoma patients with high HIF-1α
expression was observed as reported for the squamous cell
caricnoma in head and neck region, oral cavity and uterine
cervix [26,27,30,31]. Other did not find prognostic signifi-
cance in oesophageal squamous cell carcinoma [47]. Vari-
ous factors are thought to affect the impact of HIF-1α
activation in tumor behaviour [48] including methodology,
cut off(s) and treatment modalities [26,27,30-32,47]. Lack
of CAIX and Glut-I expression along with high HIF-1α
expression in squamous cell carcinoma indicates alterna-
tive mechanism for HIF-1α upregulation [26]. Further-
more, we have shown that the patients in good prognosis
group had >50% HIF-1α positive tumor cells as reported
for its strong expression in squamous cell carcinoma of
oral cavity [27]. Diffuse HIF-1α expression based on
tumor types and its nonhypoxic activation through various
genetic alterations that might result in different outcomes
[22,26] may also explain our observation. Vascularization
was heterogenously distributed in the tumor including
tumor fronts and in the stromal tissue between the islands
of tumor cells. Perinecrotic tumor cells distant from the
supplying vessels under hypoxic stress express HIF-1α,
whereas nonnecrotic tumor shows diffuse expression
throughout the tumor including the tumor cells close to
the blood vessels [29]. Despite, the heterogenous distribu-
tion of vascularity, our observation of positive association
between HIF-1α and tumor vascularity suggests the HIF-
1α induced angiogenesis. HIF-1α is known to induce ex-
pression of various genes including genes linked to cell
survival, apoptosis, cellular proliferation [22]. Perhaps, the
better outcome in patients with high HIF-1α expressing
Figure 3 Survival curves using the Kaplan-Meier method. The
Kaplan-Meier curve of disease-specific survival in relation to the HIF-
1α showed that patients whose tumors expressed low levels of HIF-
1α had a worse prognosis than those with high levels.
Table 2 Relative risk (RR) of dying from vulvar cancer
Variables Univariate analysis Multivariate analysis
RR 95% CIa p RR 95% CIa p
Lymph node metastasis 1.99 1.49–2.65 <0.001 2.28 1.69–3.07 <0.001
Infiltration of vessel 2.20 1.36–3.58 0.001 - - -
Age 1.70 1.20–2.41 0.003 1.92 1.31–2.81 0.001
Tumor diameter 1.40 1.03–1.91 0.03 - - -
HIF-1αb 2.49 1.45–4.28 0.001 2.53 1.46–4.37 0.001
a95% confidence interval.
bLow: ≤ 50% tumor cells and high: > 50% tumor cells.
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tumors might be due to its inhibitory role on tumor cells
through induction of proapoptotic pathway [49,50].
Hypoxia markers; HIF-1α, GLUT-1, CA IX and VEGF
are expressed in both vulvar preneoplastic lesions and
invasive squamous cell carcinoma [28]. An increasing
expression of VEGF from normal epithelium to prema-
lignant lesion to invasive squamous cell carcinoma was
found in vulva [28]. In the present study, high VEGF ex-
pression was significantly associated with only poor
tumor differentiation, however, an other study reported
no such association in vulvar carcinomas [19]. We did
not find that the VEGF levels demonstrated prognostic
significance, a result being different from a report by
Obermair and colleagues [19]. A lack of correlation of
VEGF with vascularity observed in the present series which
is different from an earlier report [19], might be due to its
possible non-angiogenic effects and/or autocrine role on
tumor cells [51,52]. Alternative mechanisms of VEGF inde-
pendent neoangiogenesis by inducing other potent angio-
genic molecules like basic fibroblast growth factor and size
related proainherent angiogenic effect on the tumor [53]
may have resulted in nonsignificant relationship. We noted
no association between VEGF and HIF-1α expression pos-
sibly due to an alternative non HIF-1α mechanism of
VEGF induction [54]. The proangiogenic effect of VEGF is
closely related to the tumor size and no impact on angio-
genesis is found when tumor reaches to certain size [53].
There are several pitfalls associated to immunohisto-
chemical methods. In addition, the handling of tissue
specimens, such as fixation and storage time, may influ-
ence the immunohistochemical results [55]. The lack of
consideration for these limitations may reduce the use-
fulness of immunohistochemical studies. In the present
study, the fixation and storage time of the tissues did
not influence the CD34, HIF-1α and VEGF immuno-
staining. Both false positive and negative results may
limit the outcome of immunohistochemical studies. To
reduce the possibility of false negative results we have
used the EnVision™ Flex+ detection system reported to
have a high sensitivity [56]. Furthermore, we have in-
cluded positive controls in each run to exclude the pos-
sibility of false negative result due to methodological
problems. To avoid nonspecific staining we extensively
optimalized the dilutions of the primary antibodies used.
In addition, negative controls, replacing the primary
antibodies with the mouse myeloma protein IgG1, were
included to exclude the possibility of false positive results.
Despite the effort to quality secure immunostaining pro-
cesses there are major limitations connected to immuno-
histochemistry between the studies that are linked to
methodological differences including immunostaining
procedures and scoring systems [57]. In the future it is
clearly needed a standarization of immunohistochemical
methodology and scoring systems.
Conclusions
Our results show that high tumor vascularity in vulvar
carcinoma is associated with larger tumor size and dee-
per invasion, indicating that it is a feature of aggressive
tumor phenotype. High HIF-1α expression has favorable
prognostic impact in vulvar carcinoma patients.
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